☆ 4.7 Editorial Material

TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?

CLINICAL CANCER RESEARCH (2021)

Related references

Note: Only part of the references are listed.
Article Oncology

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model

Inhye E. Ahn et al.

Summary: This study aimed to establish a prognostic model to stratify patients into high, intermediate, and low-risk groups. The study identified TP53 aberration, prior treatment, beta-2 microglobulin level, and lactate dehydrogenase level as independent factors associated with progression-free survival and overall survival. The model was validated in internal and external validation cohorts.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Letter Hematology

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Fortunato Morabito et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection
Article Hematology

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options

Jitka Malcikova et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) carrying low-burden TP53 mutations may experience a impact on overall survival (OS), particularly in those who have not received targeted therapy. The clonal evolution of low-burden TP53 mutations is associated with the intensity of chemotherapy regimens.

BLOOD (2021)

Add to Collection
Article Oncology

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib

Christian Brieghel et al.

Summary: In chronic lymphocytic leukemia (CLL), patients with multi-hit TP53 aberrations have poorer overall survival, progression-free survival, and time-to-progression compared to those with single-hit TP53, while single-hit TP53 defines a distinct subgroup of patients with excellent response to single-agent ibrutinib. These findings highlight the importance of further investigation into prognostication and management of multi-hit TP53 CLL.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Oncology

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

John C. Byrd et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection
Review Hematology

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics

Elias Campo et al.

HAEMATOLOGICA (2018)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.